FDA Approves Cosentyx for Moderate to Severe Hidradenitis Suppurativa

The U.S. Food and Drug Administration (FDA) has approved secukinumab (Cosentyx) for the treatment of moderate to severe Hidradenitis Suppurativa (HS). This FDA Cosentyx approval marks an expansion of the drug's indications, offering a new treatment option for this chronic inflammatory skin condition where limited biologic therapies are available.

Drug Overview

Secukinumab (Cosentyx) is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A). It is now approved for the treatment of moderate to severe hidradenitis suppurativa (HS).

Clinical Insights

Clinical trials for secukinumab in HS focused on the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR), defined as at least a 50% reduction in abscess and inflammatory nodule count without an increase in abscesses or draining fistulas.

Class-typical adverse events include increased risk of infections (particularly upper respiratory tract infections), nasopharyngitis, headache, and potential exacerbation of inflammatory bowel disease. Injection site reactions and hypersensitivity have also been reported.

Regulatory Context

The FDA approval pathway for biologics in HS typically involves phased clinical trials (Phase 1-3), with pivotal Phase 3 trials demonstrating safety and efficacy. [Source: U.S. Food and Drug Administration] The Biologics License Application (BLA) submission includes comprehensive clinical data, followed by FDA review. Approval timelines vary but generally span several years from initial trials to market authorization.

Market Impact

Prior to this secukinumab approval, adalimumab was the only FDA-approved biologic for moderate to severe HS. The introduction of secukinumab offers a novel mechanism of action alternative to adalimumab, potentially addressing unmet needs due to partial responses and safety concerns, and expanding treatment options in the hidradenitis suppurativa market. The moderate to severe hidradenitis suppurativa patient population is estimated in the hundreds of thousands in the US.

Future Outlook

Secukinumab differentiates by targeting IL-17A rather than TNF-alpha, offering a new biologic option for moderate to severe hidradenitis suppurativa patients who may not respond adequately to adalimumab. This Dermatology approval may lead to further investigations into other Inflammatory Skin Diseases.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-07.